PR86753

CLEVELAND, Nov. 20, 2020 /PRNewswire=KYODO JBN/ --

MIM Software Inc., a leading global provider of medical imaging software,

announced today a collaboration with Peter MacCallum Cancer Centre (Peter Mac)

in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence

(ProsTIC) program.

Logo -  https://mma.prnewswire.com/media/709760/MIM_Software_Logo.jpg

Peter Mac and MIM Software will collaborate to improve prostate cancer patient

management through the program. ProsTIC will develop tools that aid clinicians

in oncologic cancer staging, treatment planning, therapy response assessment,

and recurrence detection.

Peter Mac introduced the ProsTIC program to expand clinical trial research,

establish an educational hub on the benefits of new technology, and conduct

further research on next-generation targets.

"The Prostate Cancer Theranostics and Imaging Centre of Excellence at Peter

MacCallum Cancer Centre in Melbourne is proud to collaborate with MIM Software

to enhance our program," said Professor Michael Hofman, Nuclear Medicine

physician, and physician-scientist at Peter Mac. "Clinical researchers will

collaborate with MIM Software to perform advanced analysis of PET images and

develop new methods for whole-body tumor analysis. We hope to identify new

prognostic or predictive imaging biomarkers and also contribute to the

development of artificial intelligence algorithms that will improve patient

outcomes through improved, personalized medicine."

PET/CT imaging is an essential tool for disease identification. However, the

process of differentiating a tumor from normal uptake on oncologic PET/CT scans

is time-consuming. There is also an immense amount of quantitative data in

these exams not currently captured and potentially important for determining a

patient's prognosis. The collection of this data will result in more

personalized patient care, including treatment response assessment.

"There is a demand for more quantitation to increase clinician confidence, and

MIM Software can play a significant role in helping to predict patient outcomes

as a result of data-driven decision-making," said Aaron Nelson, MD, Chief

Medical Officer of MIM Software Inc. "This collaboration with Peter MacCallum

Cancer Centre will help develop a reproducible and efficient method for

quantification of FDG and Ga-68 PSMA PET lesions."

About MIM Software Inc.

MIM Software is committed to enhancing patient care by providing customer-focused

and innovative imaging, workflow, and data solutions. MIM Software offers a central

software package that allows industry-leading oncology tools to be utilized together

to ensure plan quality and maximize effective data usage and efficiency.

Headquartered in Cleveland, OH, MIM Software is a privately held company with

offices worldwide.

To learn more about MIM Software, visit www.mimsoftware.com.

About The Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world-leading cancer research, education,

and treatment center, and Australia's only public health service solely

dedicated to caring for people affected by cancer.

The hospital has over 3,200 staff, including more than 700 laboratory and

clinical researchers, all focused on providing better treatments, better care,

and potential cures for cancer.

To learn more about Peter Mac and the ProsTIC program, visit

www.petermac.org/ProsTIC.

CONTACT: Nicholas Sewell, Senior Public Relations & Marketing Specialist,

+1-216-455-0765, nsewell@mimsoftware.com

SOURCE: MIM Software Inc.